BRCA2: Executive Oncology Target Assessment
This is an example Biotica Bio deliverable: a comprehensive oncology target assessment for BRCA2, generated from the Open Targets Platform API and interpreted for strategy and due diligence. The data below is derived from the Platform’s aggregated sources; the narrative and strategic synthesis are by Biotica Bio.
This assessment is for strategic and due-diligence use only; it does not constitute regulatory, medical, or investment advice.
For how this report was produced (one GraphQL query → data → narrative), see How it’s built.
Data: Open Targets Platform. Interpretation and narrative: Biotica Bio.
1. Executive summary
- Not directly drugged (0 direct drugs); opportunity is indirect and biomarker-led, not a first-in-class BRCA2 binder in the short term.
- Priority indications: breast, fanconi, breast-ovarian (scores 0.80–0.84); consider Fanconi anemia and pediatric where biology and unmet need align.
- Modality verdict: Pathway and patient selection near-term; direct SM tractability challenging, 0 high-quality chemical probes — focus on PARP and DDR combinations, biomarker-driven development.
- Competitive reality: Breast/ovarian/prostate are crowded; differentiate via combination, line of therapy, or biomarker.
2. Target and biology
BRCA2 is a protein-coding gene with primary context in DNA repair (homologous recombination) and genome stability. Reactome pathways centre on DNA Repair, Disease, Reproduction. Gene Ontology and COSMIC hallmarks support DNA binding, nucleus, and response to DNA damage. [Reactome, Gene Ontology, COSMIC]
Strategic point: Biology is mature and actionable for mechanism-based trials and combination strategies (e.g. with PARP inhibitors, chemotherapy, or other DNA damage response targets).
3. Where to play (indications)
| Disease | Score (0–1) | Therapeutic area | Priority |
|---|---|---|---|
| breast cancer | 0.84 | cancer or benign tumor; reproductive system or breast disease; integumentary system disease | Prioritise |
| breast neoplasm | 0.84 | integumentary system disease; cancer or benign tumor; reproductive system or breast disease | Prioritise |
| Fanconi anemia complementation group D1 | 0.84 | nutritional or metabolic disease; musculoskeletal or connective tissue disease; genetic, familial or congenital disease; hematologic disease; immune system disease | Prioritise |
| breast carcinoma | 0.83 | cancer or benign tumor; integumentary system disease; reproductive system or breast disease | Prioritise |
| breast-ovarian cancer, familial, susceptibility to, 2 | 0.80 | cancer or benign tumor; genetic, familial or congenital disease | Prioritise |
| ovarian neoplasm | 0.79 | cancer or benign tumor; reproductive system or breast disease; endocrine system disease | Prioritise |
| Hereditary breast and ovarian cancer syndrome | 0.79 | cancer or benign tumor; endocrine system disease; reproductive system or breast disease; integumentary system disease; genetic, familial or congenital disease | Prioritise |
Prioritise hereditary and sporadic breast, ovarian, and prostate cancer; consider Fanconi anemia and pediatric indications where biology and unmet need align. Evidence is genetics- and pathway-led (EVA, Genomics England, Reactome, Europe PMC, and others).
Commercial take: Focused indication strategy and potential pan-cancer use in biomarker-selected populations.
4. Druggability and modality
Verdict: 0 direct drugs on BRCA2; tractability challenging for direct small-molecule modulation; 0 high-quality chemical probes. PARP and other DDR agents act via synthetic lethality or pathway context, not as direct binders.
Development take: Near-term value is pathway and patient selection, not a direct inhibitor. Long-term direct modulation (e.g. stabilizers, restorers) remains speculative and would require strong new biology and chemistry.
5. Genetic constraint and safety
LoF intolerant (oe ≈ 0.71) — extreme loss-of-function intolerance and haploinsufficiency; supports tumor-suppressor and hereditary-cancer role. No target-level safety liability records in the dataset; clinical risk is mainly from pathway and indication.
Development take: Therapeutic strategies that restore or mimic function (e.g. Fanconi anemia) or exploit synthetic lethality (e.g. PARP in BRCA2-deficient tumors) align with this profile; direct LoF induction would not.
6. Prioritisation and feasibility
Validated cancer driver with strong mouse and human genetics; not pan-essential in DepMap (context-dependent essentiality). Main development challenges are modality (direct vs indirect) and competitive landscape (PARP, combinations, biomarkers), not lack of biological rationale.
7. DepMap and cellular dependency
Not pan-essential; essentiality is context-dependent (e.g. in BRCA2-deficient or HRR-defective backgrounds). Supports synthetic lethality and combination strategies rather than monotherapy targeting in unselected populations. [DepMap]
8. Expression and literature
Broad expression (110+ tissue/biosample entries); 34k+ publications in the platform — strong evidence base for regulatory and payer narratives and for mechanism-of-action and biomarker discussions. [Expression Atlas, Human Protein Atlas, Europe PMC]
Key papers (evidence-backed and hallmark): 14681210, 25833843, 24902638, 32005245, 40724944.
9. Strategic synthesis and recommendations
- Indication focus — Prioritise hereditary and sporadic breast, ovarian, and prostate cancer; consider Fanconi anemia and pediatric (e.g. medulloblastoma) where biology and unmet need align.
- Modality — Short-to-mid term: maximise indirect approaches (PARP and beyond, DDR combinations) and biomarker-driven development (germline/somatic BRCA2, HRR signatures). Longer term: pursue direct BRCA2 modulation only if strong new biology and chemistry emerge.
- Competitive and development risk — Differentiation via combination, line of therapy, biomarker, or formulation is critical; genetic constraint and driver status support patient selection to maximise benefit and support labelling.
- Evidence use — Use the large evidence base for target validation narratives, regulatory packages, and payer/HTA discussions; keep updates aligned with Open Targets and other public evidence.
10. Data provenance and methodology
Report generated from the Open Targets Platform GraphQL API (https://api.platform.opentargets.org/api/v4/graphql). Query: comprehensive oncology target assessment (target, pathways, GO, hallmarks, tractability, known drugs, associated diseases, evidence, DepMap, prioritisation, safety, expression, genetic constraint, literature, interactions; plus disease-level data for competitors/comparables). Target: BRCA2 (ENSG00000139618). Re-run the oncology query for this ID (or other targets) to refresh the underlying data; interpretation and strategic narrative are by Biotica Bio.
11. Competitive reality
Source: Open Targets Platform disease(efoId).knownDrugs, disease(efoId).associatedTargets, and target.interactions. Indication set: breast carcinoma, ovarian carcinoma, prostate cancer, neoplasm.
Breast carcinoma and related indications have many approved drugs and phase II+ candidates; ovarian and prostate are similarly active. BRCA2 is not directly targeted — the competitive set is indication-space and pathway-adjacent.
Key competitors
| Drug | Target | Phase | Mechanism | Indication |
|---|---|---|---|---|
| EXEMESTANE | cytochrome P450 family 19 subfamily A member 1 | 4 | Cytochrome P450 19A1 inhibitor | breast carcinoma |
| GOSERELIN ACETATE | gonadotropin releasing hormone receptor | 4 | Gonadotropin-releasing hormone receptor agonist | breast carcinoma |
| TOREMIFENE CITRATE | estrogen receptor 1 | 4 | Estrogen receptor modulator | breast carcinoma |
| BEVACIZUMAB | vascular endothelial growth factor A | 4 | Vascular endothelial growth factor A inhibitor | breast carcinoma |
| TRASTUZUMAB | erb-b2 receptor tyrosine kinase 2 | 4 | Receptor protein-tyrosine kinase erbB-2 inhibitor | breast carcinoma |
| IXABEPILONE | tubulin beta 1 class VI | 4 | Tubulin inhibitor | breast carcinoma |
| IXABEPILONE | tubulin beta 2A class IIa | 4 | Tubulin inhibitor | breast carcinoma |
Key comparable targets
| Target | Role |
|---|---|
| BRCA1, BRCA1 DNA repair associated | — |
| PALB2, partner and localizer of BRCA2 | — |
| TP53, tumor protein p53 | — |
| PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | — |
| CHEK2, checkpoint kinase 2 | — |
| ATM, ATM serine/threonine kinase | — |
| RAD51C, RAD51 paralog C | — |
Pathway neighbours available in Platform (target.interactions).
Commercial take: Crowded landscape; differentiate via combination, line of therapy, biomarker, or formulation.
12. Commercial opportunity map
Feasibility and competition context informed by Open Targets (disease.knownDrugs, associatedTargets).
Revenue-generating strategies (ranked)
| Strategy | Feasibility | Revenue potential | Reality check |
|---|---|---|---|
| Biomarker-driven trial enrichment | High | High | Already standard; still expandable |
| PARP + novel combo (ATR, POLθ) | High | Very high | Competitive but still open |
| Resistance reversal therapies | Medium | Very high | Underserved, high-value niche |
| Fanconi anemia gene restoration | Medium | Medium | Orphan economics |
| Direct BRCA2 modulation | Low | Unknown | Long-term science project |
Alpha insight
The opportunity is not BRCA2 per se but the dynamic loss and restoration of BRCA2 function over time. That unlocks resistance tracking, adaptive therapy, and sequencing strategies—and justifies investment in biomarkers and combinations that address reversion and HR restoration, not only front-line synthetic lethality.
Near-term wedge
The most valuable near-term wedge is BRCA2 + longitudinal biomarker platform: detecting reversion mutations, HR restoration, and therapy escape. That supports diagnostics, trial enablement, and pharma partnerships without requiring a direct BRCA2 drug.
Data: Open Targets Platform. Interpretation and narrative: Biotica Bio. For methodology, see How it’s built.